SIB 1508Y maleateCAS# 192231-16-6 |
- PHA-665752
Catalog No.:BCC1181
CAS No.:477575-56-7
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
- Tivantinib (ARQ 197)
Catalog No.:BCC3688
CAS No.:905854-02-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 192231-16-6 | SDF | Download SDF |
| PubChem ID | 6442277 | Appearance | Powder |
| Formula | C16H18N2O4 | M.Wt | 302.33 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in water and to 50 mM in DMSO | ||
| Chemical Name | (E)-but-2-enedioic acid;3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine | ||
| SMILES | CN1CCCC1C2=CN=CC(=C2)C#C.C(=CC(=O)O)C(=O)O | ||
| Standard InChIKey | BCPPKHPWLRPWBJ-WLHGVMLRSA-N | ||
| Standard InChI | InChI=1S/C12H14N2.C4H4O4/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2;5-3(6)1-2-4(7)8/h1,7-9,12H,4-6H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent neuronal nicotinic ACh receptor agonist (EC50 values are 1.8, 5, 9 and 23 nM for α4β2, α2β4, α4β4 and α3β4 receptors respectively). Improves cognitive function in a MPTP-induced model of Parkinson's Disease in vivo. |
SIB 1508Y maleate Dilution Calculator
SIB 1508Y maleate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.3076 mL | 16.5382 mL | 33.0764 mL | 66.1529 mL | 82.6911 mL |
| 5 mM | 0.6615 mL | 3.3076 mL | 6.6153 mL | 13.2306 mL | 16.5382 mL |
| 10 mM | 0.3308 mL | 1.6538 mL | 3.3076 mL | 6.6153 mL | 8.2691 mL |
| 50 mM | 0.0662 mL | 0.3308 mL | 0.6615 mL | 1.3231 mL | 1.6538 mL |
| 100 mM | 0.0331 mL | 0.1654 mL | 0.3308 mL | 0.6615 mL | 0.8269 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Galanganone C
Catalog No.:BCN7486
CAS No.:1922129-46-1
- Galanganone B
Catalog No.:BCN7485
CAS No.:1922129-43-8
- Galanganone A
Catalog No.:BCN7484
CAS No.:1922129-42-7
- Carboxypeptidase G2 (CPG2) Inhibitor
Catalog No.:BCC1452
CAS No.:192203-60-4
- Tipifarnib (Zarnestra)
Catalog No.:BCC2253
CAS No.:192185-72-1
- Prazosin
Catalog No.:BCC4081
CAS No.:19216-56-9
- Harpagoside
Catalog No.:BCN4995
CAS No.:19210-12-9
- MRS 1334
Catalog No.:BCC5753
CAS No.:192053-05-7
- Tenulin
Catalog No.:BCN7961
CAS No.:19202-92-7
- Hinokiflavone
Catalog No.:BCN2989
CAS No.:19202-36-9
- 12-Hydroxymyricanone
Catalog No.:BCN8046
CAS No.:191999-68-5
- HIV-1 Tat Protein Peptide
Catalog No.:BCC4417
CAS No.:191936-91-1
- CGP 71683 hydrochloride
Catalog No.:BCC7283
CAS No.:192322-50-2
- Prazosin HCl
Catalog No.:BCC2505
CAS No.:19237-84-4
- Neuropeptide AF (human)
Catalog No.:BCC5854
CAS No.:192387-38-5
- Neuropeptide SF (human)
Catalog No.:BCC5829
CAS No.:192387-39-6
- Lomeguatrib
Catalog No.:BCC1133
CAS No.:192441-08-0
- Ergosta-4,6,8(14),22-tetraen-3-one
Catalog No.:BCN1183
CAS No.:19254-69-4
- 9alpha,11,12-Trihydroxydrim-7-en-6-one
Catalog No.:BCN7388
CAS No.:192566-65-7
- 11α-Hydroxycanrenone
Catalog No.:BCC8433
CAS No.:192569-17-8
- PPADS tetrasodium salt
Catalog No.:BCC6725
CAS No.:192575-19-2
- 9-Benzoylcarbazole
Catalog No.:BCC8799
CAS No.:19264-68-7
- H-DL-HoSer-OH
Catalog No.:BCC3242
CAS No.:1927-25-9
- PD 161570
Catalog No.:BCC7765
CAS No.:192705-80-9
Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.[Pubmed:10411585]
J Pharmacol Exp Ther. 1999 Aug;290(2):731-9.
Monkeys that receive chronic low-dose 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) administration have difficulty performing numerous cognitive tasks. This study further examines the extent to which chronic low-dose MPTP exposure affects performance of a visual memory task [variable delayed response (VDR)] with both attentional and short-term memory components and assesses the effects of the novel neuronal nicotinic acetylcholine receptor agonist SIB-1508Y and levodopa on cognitive task performance. Before MPTP treatment, these monkeys displayed a delay-dependent decrement in performance on the VDR task and performed well on delayed matching-to-sample and visual pattern discrimination tasks. Chronic low-dose MPTP treatment caused a shift to a delay-independent pattern of responding on the VDR task, such that short-delay trials were performed as poorly as long-delay trials. There were also deficits in performing the delayed matching-to-sample task, whereas visual discrimination performance remained intact. SIB-1508Y normalized the pattern of response on the VDR task by significantly improving performance on short-delay trials and on the delayed matching-to-sample task. These effects lasted up to 24 to 48 h after SIB-1508Y administration. Neither levodopa nor nicotine significantly improved task performance. These results suggest that chronic low-dose MPTP exposure results in a cognitive disturbance that can be corrected by the nicotinic acetylcholine receptor agonist SIB-1508Y but not by levodopa. Thus, SIB-1508Y may be useful in the treatment of the cognitive deficits in Parkinson's disease.
